HonCode

Go Back   HER2 Support Group Forums > Breast Cancer Newsfeed
Reload this Page Teva Announces Successful Results Of Phase III Study Of Its Long-Acting G-CSF Product
Register Gallery FAQ Members List Calendar Today's Posts

Reply
 
Thread Tools Display Modes
Old 06-07-2011, 10:10 AM   #1
News
Senior Member
 
News's Avatar
 
Join Date: Oct 2007
Posts: 18,981
Teva Announces Successful Results Of Phase III Study Of Its Long-Acting G-CSF Product
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today that lipegfilgrastim (INN; internal code - XM22) achieved its primary endpoint of reducing the duration of severe neutropenia in a Phase III study designed to evaluate the efficacy and safety of lipegfilgrastim (XM22) compared to pegfilgrastim (Amgen's Neulasta?)...

More...
News is offline   Reply With Quote
Reply

« Previous Thread | Next Thread »

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts
BB code is On
Smilies are On
[IMG] code is On
HTML code is Off
Forum Jump


All times are GMT -7. The time now is 07:18 PM.
Contact Us - HER2 Support Group - Archive - Privacy Statement - Top

Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021
free webpage hit counter